Figure 1 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

<p>Plasma concentration for copanlisib (BAY 80-6946). Plasma concentration of copanlisib (BAY 80-6946) was measured in samples from nine patients collected on cycle 1 day 15 before infusion (pre-dose) and at 0.5, 1, 2, 4, 6, 8, and 24 hours after infusion. Eight patients received copanlisib 45...

全面介绍

Saved in:

书目详细资料
主要作者:	Andre L. De Souza (22819921) (author)
其他作者:	Matthew J. Hadfield (22819924) (author), Shaolei Lu (22819927) (author), Dragan J. Golijanin (22819930) (author), Roxanne Wood (22819933) (author), Jeannine Margolis (22819936) (author), Kate Anderson (22819939) (author), Adam J. Olszewski (15129834) (author), Sheldon L. Holder (22819942) (author), Wafik S. El-Deiry (15170575) (author), Rahul R. Aggarwal (15132918) (author), Anthony E. Mega (22819945) (author), Benedito A. Carneiro (15925723) (author)
出版:	2025
主题:	Cancer Therapeutic Research and Development Clinical Research and Trials Clinical Trial Results Phase I Clinical Trials Prostate Cancer Small Molecule Agents DNA-reactive agents
标签:	添加标签没有标签, 成为第一个标记此记录!

Figure 1 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

相似书籍